serelaxin

This page shows the latest serelaxin news and features for those working in and with pharma, biotech and healthcare.

New drugs can't keep Novartis sales on the up

year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back Novartis' profits, forcing the company to take a charge of $200m in the quarter.

Latest news

What future for serelaxin after phase III miss?

What future for serelaxin after phase III miss? Novartis' acute heart failure therapy misses two main endpoints. ... credibility". Novartis had been hoping to build a valuable heart failure franchise around serelaxin for AHF and Entresto (sacubitril and
Novartis boosts cardiovascular pipeline with $1bn Ionis deal

The company launched first-in-class chronic heart failure therapy Entresto (sacubitril and valsartan) in 2015 and is hoping to re-file acute heart failure candidate serelaxin (RLX030) this year.
Novartis says Cosentyx is 'outpacing competitors'

These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.
Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a
CHMP turns down Avastin for brain cancer

heart failure drug Reasanz (serelaxin).

More from news
Approximately 11 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Other candidates in mid-stage testing include: natriuretic peptide receptor agonists from Capricor Therapeutics (cenderitide) and Palatin Technologies (PL-3994); Novartis' synthetic human relaxin 2 hormone serelaxin (knocked back by regulators
Interview: Elmar Schnee, Cardiorentis

It's a company with great potential, according to Schnee, who has high hopes for its lead drug candidate ularitide – an investigational product that is in competition with Novartis' serelaxin to ... Because of the serelaxin trial [by Novartis], you saw

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer: Great salary and benefits

Scientific Director: Great salary and bebefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Programme Executive: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager / Account Director: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer: Great salary and bebefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Account Manager – Med Comms – London: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Subscribe to our email news alerts

PMHub

Add my company

Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit: What does it mean for the life science sector?...
The Holy Grail of HCP Access: This is the data you need to gain access....